- Pitch Reviews
- Posts
- Invest in Rapid at Home Blood Testing Backed by Y-Combinator
Invest in Rapid at Home Blood Testing Backed by Y-Combinator
Plus, the future of office space with CBRE.
Heyyyo,
I’m writing today’s pitch review from the delivery room at CDH (about to welcome our second baby girl into the world :) So, let’s keep this brief shall we…
Quick recap from last week, I shared my purchase of Coursera’s IPO at $38 — today we’re at $50, up a cool 30%. I hope y’all jumped on it!
Shoutout to our sponsors at M1 Finance: the finance super app that makes money management easier, smarter, and more automated than ever 👉 sign-up now and get $30 when going to M1finance.com/kitun.
For my newbs; every week I breakdown a startup pitch with the added hook that you don’t have to be a rich guy to invest (if you don't know what that means, click here).
If you like what you see here and haven’t already subscribed, please do 👇👇👇
On The Pod: If you ask me WFH can stay for all of eternity, but if you ask Google and dozens of other major companies leasing up space in Chicago (and across the country) it certainly appears I’m in the minority there — that said, figuring out office space is a legit problem for a lot of owners and founders. So, rather than pontificate with a clear bias, I invited my friends Brad and Tony from CBRE Chicago on the pod!
Here’s my podcast with CBRE Vice Chairman Brad Serot and VP Tony Coglianese 👉 https://spoti.fi/3sYzWru
Follow me on Twitter @kitun.
Scott
#pitchreview time!
Company Bio
InnaMed makes monitoring and analyzing blood test data fast and seamless by providing an all-in-one platform that will capture, analyze and distribute test data in a way that is not only fast, but drastically reduces the need to visit a doctor. Additionally, they’re launching a digital platform which allows you to access and experience digital health services.
If you know anyone that is constantly in-need of blood testing, participating in trials or experimental healthcare or should be but isn’t because it’s impossible to navigate — InnaMed is for you. Also, no, this is not like Theranos. I asked (literally my first question to the founder). This is proven tech and science that has been in use for years, but never like this. They solve a massive problem for both healthcare workers and patients and the Teleheath opportunity they’re going after is literally trillions of dollars globally (just ask Glen Tullman!)
Meet the Founder
Watch my full interview with InnaMed’s CEO Eshwar Inapuri, here.
Eshwar is a Y Combinator-backed founder and bioengineer. Before starting InnaMed, he conducted R&D at UPenn for 4+ years combining microfluidics, optics and cloud computing to develop proteomics. Eshwar’s work is published in PNAS and exclusively licensed to another venture-backed startup.
Traction
Raised $2M+, backed by Y Combinator and leading Silicon Valley investors
$1.4M+ in revenue in 2020 (6x YoY) from ongoing, multi-year pharmaceutical R&D collaborations
Received grants from NASA and US Dept. of Health & Human Services for innovative HomeLab® technology
9 patent applications and 5 peer-reviewed publications on technology
Initially targeted towards specific clinical applications totaling $5B+ in market potential
Led by innovators from UPenn and experienced execs from UCSF, Duke, $ASND, $ABT, and $CDNA
Terms & Takeaway
Invest in InnaMed here 👉 https://bit.ly/3wHmmuS
Security Type: SAFE
Valuation Cap: $25,000,000
Raised (as of publishing): $836,385
Minimum Investment: $100
Here's what I like: I absolutely love the founder (I actually interviewed him a few years back on my WGN Radio show). I (and my stonk portfolio) are hot for Telehealth because the problem/solution set are beyond obvious. I think if InnaMed gets this right, it will be EVERYWHERE! It’s Alexa Show with a scanner — feeling under the weather, scan and talk to a doctor immediately.
Here's what I don't love: There’s going to be a TON of competition and the tech isn’t exactly new or protectable — accuracy is, however. If their product is superior, they will win, if not, marketing and sales will be the only defense mechanism. Beyond the competitive landscape, there’s really nothing not to like here. Amazing founder, access to capital, great strategics and green field that spans the globe.
If I had to nitpick, the $25m value cap is steep, I’d like it closer to $15m at this stage; but, if it weren’t for Reg CF we couldn’t invest anyways.
Who should invest and why: If you invested in Livongo’s IPO, stuck with Teladoc when they acquired Livongo and went shopping for more Telehealth companies this has your name all over it. Additionally, if you or loved ones deal with constant doctor visits or blood testing, investing in startups that push that space forward is the best way to help. And, lastly, if you’re the type to throw in on high risk, high reward startups in massive markets InnaMed has it all.
As always, startup investing is super high-risk, anything can happen. So, don't invest money you can’t burn on a giant Amazon DigiDoctor 🚑 💸
Invest in InnaMed here 👉 https://bit.ly/3wHmmuS
Questions? DM me on Twitter @kitun